1H26 Net Profit Above Expectations; Target Price Raised to Rmb26; Neutral Maintained
AI summary card
1H26 Net Profit Above Expectations; Target Price Raised to Rmb26; Neutral Maintained
Revenue rose 7% YoY and was in line with expectations, while net profit increased 6% YoY, exceeding expectations on lower expense ratios; the anesthetics business grew moderately and CNS drugs maintained rapid growth.
- 1H26 revenue was Rmb3,218mn, up 7% YoY and broadly in line with Goldman Sachs expectations.
- 1H26 net profit was Rmb741mn, up 6% YoY and above Goldman Sachs' Rmb697mn forecast, mainly driven by lower-than-expected R&D and administrative expenses.
- Anesthetic drugs accounted for 52% of 1H26 revenue and grew 2% YoY; CNS drugs grew 33% YoY but represented only 7% of revenue.
- NH600001 has submitted an NDA and is expected to be approved within 2026; NHL35700, for schizophrenia treatment, entered Phase II clinical trials in June 2026.
- The target price is raised from Rmb23 to Rmb26, with a Neutral rating maintained.
Report interpretation
Overview
Jiangsu Nhwa Pharmaceutical reported 1H26 results, with revenue in line with expectations and net profit above expectations, driven by lower-than-expected R&D and administrative expenses. The company is an important producer of psychotropic and anesthetic drugs in China and also operates pharmaceutical distribution and retail businesses.
Core views
Analysts raised earnings forecasts and the target price to Rmb26, mainly reflecting improved expense ratios. Growth drivers include the ramp-up of the in-licensed product TRV-130 and newly approved generic drugs; however, as the company's forward P/E is at the midpoint of its past five-year range, the current valuation is considered fair, and the Neutral rating is maintained.
Analysis framework
Based on a comparison of reported results with Goldman Sachs forecasts, and incorporating revenue growth by business segment, innovative drug R&D progress, changes in expense ratios, and peer valuations, earnings forecasts for 2026E-2028E and the 12-month target price were updated.
Methodology notes
The target valuation multiple is set based on 2026E global peer P/E multiples and adjusted using a long-term discounting approach.
The 12-month target price of Rmb26 is based on a five-year discounted P/E methodology, using a 37.5% A/H premium, 10% WACC, and a 17x 2026E target P/E for global peers.
Reported revenue and profit are compared with analyst forecasts to identify the sources of earnings deviations.
Revenue was broadly in line with expectations, while the net profit beat was mainly due to lower-than-expected R&D and administrative expenses.
Asset mapping & comparison
Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).
- 002262.SZReport Coverage Target
- Strengths
- Established business foundation in psychotropic and anesthetic drugs; rapid CNS drug growth; improved expense ratios; innovative drugs and in-licensed products offer potential incremental growth.
- Weaknesses
- Core anesthetic drug business grew only 2%; CNS drugs currently account for a low share of revenue; valuation is at the midpoint of its historical range.
- Comparison
- 2026E P/E is 17.2x; the target valuation references a 17x 2026E P/E for global peers and applies a 37.5% A/H premium.
- Risks
- Tendering or bidding execution below expectations, price declines for key products, and higher costs or risks in generic drug R&D.
Key data
- 1H26 RevenueRmb3,218mn, up 7% YoYGoldman Sachs forecast Rmb3,187mn; performance was broadly in line with expectations.
- 1H26 Net ProfitRmb741mn, up 6% YoYAbove Goldman Sachs' Rmb697mn forecast, driven by lower-than-expected R&D and administrative expenses.
- Anesthetic Drug Revenue52% of 1H26 revenue, up 2% YoYThe company's largest revenue source, but with relatively moderate growth.
- Central Nervous System Drug Revenue7% of 1H26 revenue, up 33% YoYGrowth remained strong, though the current revenue contribution is still small.
- 2026E EPSRmb1.26Above the previous forecast of Rmb1.10.
- 12-month Target PriceRmb26Previously Rmb23; reference price of Rmb21.67, implying 20% upside.
Impact & implications
The profit beat from improved cost control supports higher earnings forecasts and a higher target price, but the rating was not upgraded, reflecting a still-balanced valuation and risk-reward profile. Further valuation re-rating will depend more on the ramp-up of TRV-130, the pace of new product launches, and the sustainability of CNS drug growth.
Risks
- Tender award implementation is slower than expected.
- Price erosion in key products.
- Generic drug R&D faces higher risks or costs.
- Anesthetic drugs may be affected by volume-based procurement.
- Approval or launch progress for innovative products falls short of expectations.
What to watch
- The ramp-up pace of TRV-130.
- Approval progress for NH600001 within 2026.
- Progress of NHL35700's Phase II clinical trial.
- Volume-based procurement policies for anesthetic drugs and their impact on pricing and volumes.
- Timing of new product launches and the ramp-up pace of second-tier products.